EUCTR2017-004324-30-ES进行中（未招募）1 期
A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally- recurrent or metastatic breast cancer patients after progression on endocrine therapy (REVERT) - REVERT
Medica Scientia Innovation Research (MEDSIR)0 个研究点目标入组 60 人开始时间: 2018年11月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients are eligible for inclusion only if they meet ALL of the following criteria:
- •1. Patients have been informed about the nature of study, and have agreed to participate in the study, and signed the informed consent approved by the institution’s independent ethical committee/institutional review board.
- •2. Female patients over 18 years of age.
- •3. Patients with a histologically confirmed diagnosis of ER-positive and/or PR-positive breast cancer by local laboratory.
- •4. Patients with HER2-negative breast cancer through in situ hybridization test (fluorescence in situ hybridization [FISH], chromogenic in situ hybridization [CISH], or silver enhanced in situ hybridization [SISH]) or negative immunohistochemical status of 0 or 1+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing.
- •5. Unresectable locally advanced or metastatic breast cancer.
- •6. Confirmed disease progression while in the last aromatase inhibition- containing regimen in the metastatic setting (Note: not necessarily in the treatment line immediately prior to study entry) or within 6 months from last AI dose in the adjuvant setting. Treatment with prior CDK4/6 or mTOR inhibitor therapy is allowed.
- •7. At least one taxane or anthracycline regimen in either the adjuvant or the neoadjuvant setting.
- •8. Patients with no prior line of chemotherapy in the metastatic setting.
- •9. At least 1 and up to 3 prior lines of endocrine therapy in the metastatic setting (except for patients progressing during the adjuvant setting or before 6 months after completing adjuvant endocrine therapy).
- •10. Eastern Cooperative Oncology Group (ECOG) score 0 or 1.
- •11. Patients have adequate bone marrow and organ function as defined by the following laboratory values:
- •-Absolute neutrophil count (ANC) = 1.5 x 109 /L.
- •-Platelets = 100 x 109 /L.
- •-Hemoglobin = 9 g/dL.
- •-Sodium, potassium, calcium (corrected for serum albumin), and magnesium within normal limits for the institution.
- •-Adequate renal function as evidenced by calculated creatinine clearance =50 mL/min per the Cockcroft and Gault formula: Cr.Cl.= 0.85 * ((140 – Age years) / (SerumCreat mg/dL)) * (Weight Kg / 72).
- •-Adequate liver function as evidenced by bilirubin =1.5 times the upper limit of normal (ULN), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) =3×ULN (in the case of liver metastases =5×ULN).
- •12. Patients must have measurable disease (according to RECIST criteria v.1.1).
- •13. Premenopausal and postmenopausal women. Premenopausal women must be treated, with LHRH analogues for at least 28 days (if shorter LHRH treatment period, post-menopausal estrogen levels must be confirmed on laboratory assessments) prior to study entry. Premenopausal or postmenopausal status should have been established before starting the previous treatment with an AI +/- LHRH analogue based on the following classification:
- •Postmenopausal status is defined as either:
- •a) Prior bilateral oophorectomy
- •b) Age > 60 years
- •c) Age < 60 years and amenorrheic for 12 months in the abs
排除标准
- •Patients will be excluded from the study if they meet ANY of the following criteria:
- •1. Have received radiation therapy or limited-field palliative radiotherapy within two weeks prior to Cycle 1, Day 1, or patients who have not recovered from radiotherapy-related toxicities to baseline or grade £ 1 (except alopecia) and/or from whom =25% of the bone marrow has been previously irradiated.
- •2. Have received prior chemotherapy for locally advanced or metastatic disease.
- •3. Have peripheral neuropathy grade 2 or greater.
- •4. QTc >480 msec on basal assessments, history of congenital or personal history of long QT syndrome, Brugada syndrome, or Torsade de Pointes (TdP), or uncontrolled electrolyte disorders
- •5. Child-bearing potential women not using highly effective methods of contraception (contraception should continue during dosing and up to 90 days after study drugs discontinuation).
- •6. Known hypersensitivity to eribulin, endocrine therapy or its excipients.
- •7. Other malignancies within the previous two years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of cervix or breast.
- •8. Known uncontrolled metastases to the central nervous system (CNS) or any progressing CNS disease. (Note: Known brain metastases are considered active, if brain imaging during screening demonstrates progression of existing metastases and/or appearance of new lesions compared to brain imaging performed at least four weeks earlier and/or neurological symptoms attributed to brain metastases have not returned to baseline and/or steroids were used for brain metastases within 28 days of randomization)
- •9. Have a serious concomitant systemic disorder (e.g. active infection including HIV, or cardiac disease) incompatible with the study (at the discretion of investigator)
- •10. Major surgical procedure (defined as requiring general anaesthesia) or significant traumatic injury within 28 days prior to randomization, or patients who have not recovered from the side effects of any major surgery, or patients that may require major surgery during the course of the study.
- •11. Have received any anti-cancer biology or investigational treatment within 30 days prior to randomization.
研究者
相似试验
招募中
2 期
A multicenter phase II randomized trial to evaluate systemic therapy versus systemic therapy in combination with stereotactic radiotherapy in patients with metastatic colorectal cancerBowel cancerrectum cancer1001799010017991colon cancerNL-OMON52282niversitair Medisch Centrum Utrecht105
招募中
2 期
A multicenter randomized phase II trial evaluating the efficacy and safety of intrapericardial left superior pulmonary vein ligation or division for prevention of thrombosis in the stumpmalignant tumor of the lungJPRN-UMIN000036037iigata Chest Surgery Study Group60
进行中（未招募）
1 期
A multicenter, randomized, phase II clinical trial to evaluate the effect of Avastin in combination with neoadjuvant treatment regimens on the molecular and metabolic characteristics and changes in the primary tumors with reference to the obtained responses in patients with large primary HER2 negative breast cancers. - Neo-AvaHER2 negative breast cancerEUCTR2008-003006-34-NOOslo Universitetssykehus200
进行中（未招募）
不适用
A multicenter randomized phase II Trial assessing the activity of Gemcitabine - Oxaliplatin chemotherapy alone or in combination with Cetuximab in patients with advanced biliary cancer - BINGOadenocarcinoma of the biliary tract ( gallbladder, intra and/ or extrahepatic bile ducts, ampulla of Vater)EUCTR2007-001200-20-DEMedizinische Hochschule Hannover100
进行中（未招募）
不适用
A Phase II, randomised, multicentre study to evaluate the efficacy and safety of pazopanib in combination with pemetrexed versus cisplatin plus pemetrexed, as first-line therapy in subjects with stage IIIB/IV non-small cell lung cancerHistologically- or cytologically-confirmed diagnosis of non-predominantly squamous cell Stage IIIBwet (with confirmed malignant pleural effusion) or Stage IV NSCLCMedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2008-002144-42-DKGlaxoSmithKline R&D Limited150